RT Journal Article
SR Electronic
T1 Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.11.21255153
DO 10.1101/2021.04.11.21255153
A1 Mishra, Pankaj Kumar
A1 Bruiners, Natalie
A1 Ukey, Rahul
A1 Datta, Pratik
A1 Onyuka, Alberta
A1 Handler, Deborah
A1 Hussain, Sabiha
A1 Honnen, William
A1 Singh, Sukhwinder
A1 Guerrini, Valentina
A1 Yin, Yue
A1 Dewald, Hannah
A1 Choudhary, Alok
A1 Horton, Daniel B.
A1 Barrett, Emily S.
A1 Roy, Jason
A1 Weiss, Stanley H.
A1 Fitzgerald-Bocarsly, Patricia
A1 Blaser, Martin J.
A1 Carson, Jeffrey L.
A1 Panettieri, Reynold A.
A1 Lardizabal, Alfred
A1 Chang, Theresa Li-Yun
A1 Pinter, Abraham
A1 Gennaro, Maria Laura
YR 2021
UL http://medrxiv.org/content/early/2021/04/14/2021.04.11.21255153.abstract
AB Given the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the recent implementation of SARS-CoV-2 vaccination, we have much to learn about the duration of immune protection and the interface between the immune responses to infection and to vaccination. To address these questions, we monitored immune responses to SARS-CoV-2 infection in convalescent individuals over seven months and following mRNA vaccination. Spike Receptor-Binding-Domain (RBD)-specific circulating antibodies and plasma neutralizing activity generally decreased over time, whereas RBD-specific memory B cells persisted. Additionally, using antibody depletion techniques, we showed that the neutralizing activity of plasma specifically resides in the anti-RBD antibodies. More vigorous antibody and B cell responses to vaccination were observed in previously infected subjects relative to uninfected comparators, presumably due to immune priming by infection. SARS-CoV-2 infection also led to increased numbers of double negative B memory cells, which are described as a dysfunctional B cell subset. This effect was reversed by SARS-CoV-2 vaccination, providing a potential mechanistic explanation for the vaccination-induced reduction in symptoms in patients with “Long-COVID”.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a prospective study for research.Funding StatementThis work was funded by NIH grants R01HL149450, R01HL149450-S1, U01 AI122285-S1, and UL1 TR003017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of the Rutgers New Jersey Medical School, IRB approval No. : Pro0119980237 and Pro20150001314All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are all listed in the article and available from the corresponding author upon reasonable request.